Biopharma · FDA Approvals · Stock

COCP Cocrystal Pharma

Cocrystal Pharma Inc is a biotechnology company discovering and developing novel antiviral therapeutics that target the replication machinery of influenza viruses, hepatitis C viruses, and noroviruses. It employs structure-based technologies and Nobel Prize-winning expertise to create first and in-class antiviral drugs…

Assets on file: CDI-988

Start live analysis of COCP Run 8-agent AI analysis All sector events →

Catalyst calendar

Dated catalysts for COCP, including recently decided ones.

October 2026

Oct 2026

Oct 1, 2026

30 days ago

COCPCocrystal Pharma, Inc.

CDI-988: Phase 1/Phase 2 trial NCT07198139 expected to finish collecting primary-endpoint data (topline results usually follow)

Trial primary completionOutcome not recordedClinicalTrials.gov

Recent first-hand events

Every first-hand event for COCP, newest first.

Instant stream — events appear as soon as they are filed.

Decision-gradeMaterialNotableMinor

Oct 22, 2026

03:23 PM

COCPCocrystal Pharma, Inc.

CDI-988 · NCT07198139 registry update

status: RECRUITING → COMPLETED; primary_completion: 2026-10-01 → 2026-09-14; completion: 2026-12-01 → 2026-09-14; enrollment: 40 → 32

Trial registry changeClinicalTrials.gov Open record

Apr 30, 2026

08:30 PM

COCPCocrystal Pharma, Inc.

COCP presents CDI-988 Phase 1b norovirus study at ICAR 2026

Cocrystal presented mechanism-of-action and Phase 1b progress for oral protease inhibitor CDI-988 at ICAR 2026. The first cohort of the ongoing human-challenge study is fully enrolled, with prevention and treatment cohorts to follow. Fast Track designation has already been granted by FDA.

Conference presentationSEC 8-K

Apr 2, 2026

12:30 PM

COCPCocrystal Pharma, Inc.

COCP: FDA Fast Track designation for CDI-988 norovirus program

FDA granted Fast Track designation to CDI-988, enabling accelerated development, rolling NDA review, and potential Priority Review. The designation applies to the oral protease inhibitor being developed for both treatment and prevention of norovirus infection. A Phase 1b challenge study is already underway at Emory University.

FDA designationSEC 8-K